Wang et al. [24] previously demonstrated that TUG1 was significantly upregulated in patients with PAH and that TUG1 knockdown significantly prevented the development of PAH in vivo, suggesting that TUG1 may also be a novel and promising biomarker for COPD complicated with PAH. This evidence concerns the gene TUG1 and pulmonary arterial hypertension.